Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome

Inclusion Criteria: * 1.Patients aged 18-70 years; * 2.Diagnosed with primary biliary cholangitis-autoimmune hepatitis overlap syndrome according to Paris criteria, based on liver biopsy results obtained 3 months before screening; * 3.White blood cell count ≥2.5x10\^9/L or platelet count ≥50x10\^9/L at inclusion; * 4.Agreed to participate in the trial, and assigned informed consent. Exclusion Criteria: * 1\. The presence of hepatitis A, B, C, D, or E virus infection; * 2\. Patients with indications for immunosuppressive treatment at inclusion: serum alanine transaminase(ALT) or aspartate transaminase(AST) ≥10 fold upper limit of normal(ULN)，or serum ALT or AST≥ 5 fold ULN and γglobulin level ≥ 2 fold ULN, or bridging necrosis or multiacinar necrosis on histological examination. * 3\. Patients with complications of cirrhosis; * 4\. Patients with previous treatment of immunosuppressive agents or traditional Chinese medicine for more than one month; * 5\. Primary sclerosing cholangitis,non-alcoholic steatohepatitis,drug induced liver disease or Wilson's disease confirmed by liver biopsy; * 6\. Pregnant and breeding women; * 7\. Severe disorders of other vital organs, such as severe heart failure, cancer; * 8\. Parenteral administration of blood or blood products within 6 months before screening; * 9\. Recent treatment with drugs having known liver toxicity; * 10.Taken part in other clinic trials within 6 months before screening.